Paediatric Asthma and Wheeze Study - Part 2
Using a wheeze scan device (WheezeScan) in the management of preschool wheeze and paediatric asthma: a multicentre cohort study - Part 2
Queensland University of Technology
125 participants
Feb 8, 2024
Interventional
Summary
Asthma is the most common chronic illness in children. Yet, identifying wheeze is challenging for parents (disagreement rate between doctors and parents are >50%) and indeed many cultures (including Indigenous Aus) do not have a word for wheeze. Our multicentre study addresses the need to define wheeze accurately using digital technology. We will use WheezeScan (WzS) digital technology during face-to-face clinics as well as remotely (child’s home) in Queensland (including outreach clinics), Darwin and Sydney. In 125 children aged <12 years with asthma, we aim to evaluate the impact of using WzS impacts upon asthma control assessment, PROs, self-efficacy scale and health cost. WzS’s dependable accuracy will provide parents/caregivers and doctors the ability to discern if a child is wheezing-subsequently providing the confidence and clarity over the next steps that need actioning. Our study will lead to more accurate assessment of asthma control, thus resulting in improved management. Asthma guidelines identify that the primary goal of management is achieving good asthma control, thus reducing the risk of exacerbations.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Use of WheezeScan (WzS), a portable user-friendly digital device that listens to 30sec of breathing then objectively documents wheeze using AI-informed signal processing. WzS is manufactured by Omron (Japan). Parents will be trained by the research nurses/assistants using a standard protocol provided by the manufacturers (sse link https://www.omron-healthcare.co.uk/nebulisers/wheezescan.html). Adherence will be monitored using participant diaries. Parents will use the WheezeScan at least once a day for the duration of the study (total of 5 weeks).
Locations(4)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12623000856617